This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Dosing

XALKORI (crizotinib) oral dosing is simple and convenient.1

​​​​​​​The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) taken continuously.1

If a dose is missed, then it should be taken as soon as the patient remembers, unless it is less than 6 hours until the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose.1

How to take XALKORI

The capsules should be swallowed whole preferably with water, and should not be crushed, dissolved or opened. They may be taken with or without food. Grapefruit or grapefruit juice should be avoided since it may increase crizotinib plasma concentration; St. John's wort should be avoided since it may decrease crizotinib plasma concentration.1

Available Doses

XALKORI is available in 2 dose levels to facilitate dose modification.1

  • XALKORI 200 mg hard capsules
  • XALKORI 250 mg hard capsules

Dose Modifications

Dose modifications with XALKORI are simple.1

Haematological Toxicities1*†

* Except lymphopenia (unless associated with clinical events, e.g. opportunistic infections).​​​​​​​
† For patients who develop neutropenia and leukopenia, see also sections 4.4 and 4.8 of the XALKORI Summary of Product Characteristics.​​​​​​
​​​​​​​‡ In case of recurrence, dosing should be withheld until recovery to Grade ≤2, then dosing should be resumed at 250 mg once daily. XALKORI must be permanently discontinue in case of further Grade 4 recurrence.
§ For patients treated with 250 mg once daily or whose dose was reduced to 250 mg once daily, discontinue during evaluation.

Hepatotoxicity1     

*XALKORI must be permanently discontinued in case of further Grade ≥3 recurrence. See SmPC sections 4.4 and 4.8. For patients treated with 250 mg once daily or whose dose was reduced to 250 mg once daily, discontinue during evaluation.

Monitoring​​​​1

Liver function tests including ALT/AST and total bilirubin should be monitored once a week during the first 2 months of treatment, then once a month and as clinically indicated, with more frequent repeat testing for Grade 2, 3 or 4 elevations.1

*XALKORI must be permanently discontinued in case of further Grade ≥3 recurrence. See sections 4.4 and 4.8 of the XALKORI Summary of Product Characteristics.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; ULN, upper limit of normal.

Patient ILD/ Pneumonitis1

* See sections 4.4 and 4.8 of the XALKORI Summary of Product Characteristics.

QTc Prolongation1

* XALKORI must be permanently discontinued in the case of further Grade ≥3 recurrence. See sections 4.4 and 4.8 of the XALKORI Summary of Product Characteristics.
​​​​​​​† For patients treated with 250 mg once daily or whose dose was reduced to 250 mg once daily, discontinue during evaluation.

Bradycardia1

* See sections 4.4 and 4.8 of the XALKORI Summary of Product Characteristics.
† Heart rate less than 60 beats per minute.
‡ Permanently discontinue for recurrence.​​​​​​​
§ For patients treated with 250 mg once daily or whose dose was reduced to 250 mg once daily, discontinue during evaluation.

Visual Effects1

For special warnings and precautions, and drug-drug interactions, please refer to the XALKORI Summary of Product Characteristics.


ALT: Alanine Aminotransferase;  AST: Aspartate Aminotransferase; CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ILD: Interstitial Lung Disease
PP-XLK-GBR-1163. March 2021

Indication

XALKORI as a monotherapy is indicated for:1

  • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
  • The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Register to receive tailored information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No